Cargando…
Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the...
Autores principales: | Gotti, Manuel, Defrancesco, Irene, D’Angelo, Mario, Basso, Sabrina, Crotto, Luca, Marinelli, Alfredo, Maccalli, Cristina, Iaconianni, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662555/ https://www.ncbi.nlm.nih.gov/pubmed/33193333 http://dx.doi.org/10.3389/fimmu.2020.565236 |
Ejemplares similares
-
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
por: Shi, Huan, et al.
Publicado: (2014) -
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010) -
Chimeric antigen receptor T cell: A cancer immunotherapy
por: Singh, Surjit, et al.
Publicado: (2022) -
Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2021) -
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
por: Shin, Seungyong, et al.
Publicado: (2023)